Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Vytorin by Year
Vytorin (ezetimibe/simvastatin, legacy pre-Organon spin-off) — U.S. sales ($M) ($M)
Merck Vytorin: $12M in FY2020, down 25.0% from a year earlier. No newer figure appears in the documents we track.
Where the FY2020 figure comes from
Source: Form 10-K (filed 2021-02-25) ↗
Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vytorin (ezetimibe/simvastatin, legacy pre-Organon spin-off) — U.S. sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2020 | Dec 31, 2020 | 12 | -25.0% | Form 10-K (filed 2021-02-25) ↗ |
| FY2019 | Dec 31, 2019 | 16 | +60.0% | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2018 | Dec 31, 2018 | 10 | -91.9% | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2017 | Dec 31, 2017 | 124 | -73.8% | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2016 | Dec 31, 2016 | 473 | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Breakdown
What makes up vytorin
Cite this data
StockData. (2026). Merck Vytorin ($M), annual FY2016–FY2020 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-vytorin-us
See every metric in the Merck KPI table. Data updated Oct 26, 2026.